Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884041
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884041
Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
PUBLISHED:
PAGES: 161 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market
The global diphtheria, tetanus, and pertussis (DTP) vaccines market is experiencing robust expansion driven by rising infectious disease cases, strengthened immunization programs, and advancements in vaccine technologies. According to the report, the market reached USD 10.23 billion in 2024, is expected to grow to USD 11.69 billion by 2025, and is projected to surge to USD 33.38 billion by 2032, reflecting a strong trajectory as governments and global health organizations increase vaccination coverage. With DTP vaccines essential for preventing life-threatening bacterial infections, the market continues to gain momentum across pediatric and adult immunization programs.
Market Overview
DTP vaccines protect against three severe bacterial infections-diphtheria, tetanus, and pertussis-commonly affecting infants and young children. Multiple formulations such as DTaP, Tdap, DT/Td, and combination vaccines ensure broad applicability across age groups. Rising disease incidence is a critical factor driving adoption. The WHO reported over 62,500 global pertussis cases in 2022, with 39,000 in the Western Pacific region alone, highlighting the continued threat of whooping cough. These high infection rates reinforce the need for routine childhood immunization and booster programs.
Furthermore, leading pharmaceutical companies such as GSK plc, Sanofi, Merck & Co., Serum Institute of India, Biological E Limited, and BioNet-Asia strengthen the market with continuous supply, innovation, and global distribution capabilities.
Market Growth Drivers
High Burden of Vaccine-Preventable Diseases
Growing cases of respiratory bacterial infections are one of the most significant market drivers. CDC's Provisional 2024 Report revealed 35,435 pertussis cases in 2024, with over 6,500 cases in children aged 1-6 years. This has increased the urgency for active immunization, particularly among pediatric populations.
Expanding Vaccination Programs
Governments worldwide are initiating awareness campaigns to ensure timely vaccinations. For example, in April 2025, China launched a nationwide campaign during National Children's Vaccination Day to educate families on pertussis risks and the benefits of immunization.
Similarly, GAVI's 2023 update introduced DTP booster doses and hexavalent vaccines in eligible countries, enabling broader coverage.
Market Restraints
Vaccine Hesitancy & Lack of Awareness
In low-income regions, religious misconceptions, safety concerns, and limited education restrict vaccination uptake. In the Kyrgyz Republic, more than 22,000 children remained unvaccinated by end-2024 due to refusals and misinformation, demonstrating persistent challenges.
Cold Chain Limitations
Temperature-sensitive DTP vaccines require continuous storage between 2°C-8°C. According to India's National Vaccine Wastage Assessment, 13.5% of DPT vaccines were wasted due to cold-chain failures, directly affecting supply reliability.
Market Opportunities
Growing Government Support & Funding
Governments are investing heavily in nationwide vaccination drives. For instance, India's 2025 Td Vaccination Campaign for schoolchildren enhanced booster dose coverage. Similarly, Brazil and Guyana's Cross-Border Vaccination Week (2025) aims to immunize vulnerable populations.
Shift Toward Recombinant Technologies
Modern genetic engineering methods improve immunogenicity and duration of protection. BioNet-Asia's 2024 submission to EMA for its recombinant pertussis vaccine marks a shift toward safer, more effective vaccines, fueling new market growth avenues.
Segmentation Overview
By Technology
- Inactivated vaccines dominated 2024, driven by widespread use and WHO-reported 84% infant DTP-3 coverage in 2023.
- Recombinant technologies are expected to gain traction from 2025-2032 as companies develop safer, more immunogenic formulations.
By Type
- DTaP vaccines led 2024 due to their role in infant immunization.
- Tdap vaccines continue to expand moderately for older children, adults, and pregnant women.
By Age Group
- Pediatrics dominated the market in 2024 due to high infection rates and mandatory immunization schedules.
- Adults maintain steady demand through booster doses every 10 years.
By Distribution Channel
- Government suppliers held the largest share due to national immunization programs.
- Hospital and retail pharmacies are growing as access to vaccinations expands.
Regional Insights
North America
Generated USD 5.86 billion in 2024, leading globally due to high disease reporting, advanced health systems, and strong supply chains. U.S. pertussis cases surged to 11,568 in 2024, increasing vaccination demand.
Asia Pacific
Expected to grow at the highest CAGR through 2032, driven by cost-effective vaccines, large population, and government immunization drives.
Europe
Maintains strong share with WHO-recognized regulatory facilities, such as Germany's 2024 designation of a WHO Collaborating Center for Diphtheria.
Latin America & Middle East/Africa
Show moderate but rising adoption through cross-border and rural immunization initiatives.
Conclusion
With market value rising from USD 10.23 billion (2024) to USD 33.38 billion (2032), the global DTP vaccines market is poised for strong long-term expansion. Increasing disease prevalence, large-scale immunization campaigns, and advancements in recombinant technology will continue to strengthen global vaccine coverage and market growth.
Segmentation By Technology
- Inactivated
- Others
By Type
- DTaP Vaccine
- Tdap Vaccine
- DT/ Td vaccines
- Others
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Technology, Type, Age Group, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Product Code: FBI113648
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Diseases, By Key Countries, 2024
- 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
- 4.3. Pipeline Analysis, By Key Players
- 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries
5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Technology
- 5.1.1. Inactivated
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - By Type
- 5.2.1. DTaP Vaccine
- 5.2.2. Tdap Vaccine
- 5.2.3. DT/ Td vaccines
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adolts
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Technology
- 6.1.1. Inactivated
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - By Type
- 6.2.1. DTaP Vaccine
- 6.2.2. Tdap Vaccine
- 6.2.3. DT/ Td vaccines
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adolts
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Technology
- 7.1.1. Inactivated
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - By Type
- 7.2.1. DTaP Vaccine
- 7.2.2. Tdap Vaccine
- 7.2.3. DT/ Td vaccines
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adolts
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Technology
- 8.1.1. Inactivated
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - By Type
- 8.2.1. DTaP Vaccine
- 8.2.2. Tdap Vaccine
- 8.2.3. DT/ Td vaccines
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adolts
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Technology
- 9.1.1. Inactivated
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - By Type
- 9.2.1. DTaP Vaccine
- 9.2.2. Tdap Vaccine
- 9.2.3. DT/ Td vaccines
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adolts
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Technology
- 10.1.1. Inactivated
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - By Type
- 10.2.1. DTaP Vaccine
- 10.2.2. Tdap Vaccine
- 10.2.3. DT/ Td vaccines
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adolts
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. GSK plc
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sanofi
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Boryung Biopharma Co.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Serum Institute of India Pvt. Ltd.
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. BioNet-Asia.
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Bio Farma
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Biological E Limited.
- 11.2.9.1. Overview
- 11.2.9.2. Products & services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. GSK plc
Product Code: FBI113648
List of Tables
- Table 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2033
- Table 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
- Table 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 11: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 12: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 13: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 14: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 15: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 16: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 17: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 18: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 19: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 21: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 22: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 23: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 24: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 25: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
- Table 26: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
- Table 27: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 28: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 29: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 30: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2019-2032
List of Figures
- Figure 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024 & 2032
- Figure 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024 & 2032
- Figure 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group 2024 & 2032
- Figure 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 6: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Region, 2024 & 2032
- Figure 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
- Figure 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
- Figure 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
- Figure 11: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 12: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 13: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 14: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 15: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country, 2024
- Figure 17: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
- Figure 18: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
- Figure 19: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 20: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
- Figure 21: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 22: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 23: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 24: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 25: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 26: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
- Figure 27: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
- Figure 28: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
- Figure 29: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 30: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
- Figure 31: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 32: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 33: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 35: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 36: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
- Figure 37: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
- Figure 38: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
- Figure 39: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 40: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
- Figure 41: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 42: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 43: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 44: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 45: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 46: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
- Figure 47: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2024 & 2032
- Figure 48: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2024
- Figure 49: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 50: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2024
- Figure 51: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 52: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 53: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 55: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2024 & 2032
- Figure 56: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2024
- Figure 57: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Share (%), By Company, 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.